The FDA approved Arrowhead Pharmaceuticals’ RNA interference therapy plozasiran (Redemplo) for familial chylomicronemia syndrome, marking the company’s transition to commercial-stage operations. Arrowhead said the approval follows robust efficacy and safety signals and will position the company alongside Ionis in a small rare‑disease market. Management announced a markedly lower launch price than its rival, setting up a direct commercial contest over access and reimbursement in an ultra‑specialized indication. The clearance validates systemic RNAi as a regulatory and commercial path for liver‑directed genetic medicines and establishes Arrowhead as a near‑term entrant into rare‑disease specialty markets. The approval also crystallizes competitive dynamics around pricing, market access and patent positions between RNAi and antisense incumbents. Sources: company releases and coverage of pricing strategy.